Piper Jaffray Upgrades Acorda Therapeutics To Neutral, PT Raised To $30

May 23, 2011 5:48 AM | 8 seconds read | Make a Comment

Piper Jaffray has upgraded Acorda Therapeutics

ACOR

from Underweight to Neutral and has raised the price target from $21 to $30.

Posted In: Upgrades Price Target Analyst Ratings Acorda Therapeutics Biotechnology Health Care Piper Jaffray

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.